The presence of rare mesenchymal elements in tumor stroma demonstrates the capacity of AD-MSC to survive and engraft for at least 7 days after the last implant (Fig. 4b, in yellow, as a result from the merging between CD90 and MIT in EV and sTRAIL groups). Here, THY1 is linked to neoplasm.